Preparation of conformationally constrained α2 antagonists: The bicyclo[3.1.0]hexane approach

European Journal of Organic Chemistry

Volumn , Issue 15, 2005, Pages 3360-3369

  Bonnaud, Bernard ^a   Funes, Philippe ^a   Jubault, Nathalie ^a   Vacher, Bernard ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Adrenergic antagonists; Carbenoids; Cycloaddition; Diazo compounds; Strained molecules

Indexed keywords

EID: 23044507585     PISSN: 1434193X     EISSN: None     Source Type: Journal    
DOI: 10.1002/ejoc.200500143     Document Type: Article

References (82)

1. A. M. Lands, A. Arnold, J. P. McAuliff, F. P. Luduena, T. G. Brown, Jr., Nature 1967, 214, 597-598.
2. 3) has been cloned more recently: L. J. Emorine, S. Marullo, M.-M. Briend-Sutren, G. Patey, K. Tate, C. Delavier-Klutchko, A. D. Strosberg, Science 1989, 245, 1118-1121.
3. It seems predominantly located in adipose tissues; V. A. Skeberdis, Medicina (Kaunas) 2004, 40, 407-413.
4. e ed. (Ed.: Ph. Dorosz), Maloine, 2001, p. 1485.
5. th ed. (Ed.: S. Budavari), Merck Research Laboratories: Whitehouse Station, N.J., 1996, p. 6295.
6. K. Yamamoto, O. Hornykiewicz, Progress in Neuro-Psychopharmacology & Biological Psychiatry 2004, 28, 913-922;
7. F. Colpaert, "Noradrenergic Mechanisms in Parkinson's Disease: A Theory" in Noradrenergic Mechanisms in Parkinson's Disease (Eds.: M. Briley, M. Marien), CRC Press, Inc., Boca Raton, Florida, 1994, pp. 225-254.
8. a) Dexefaroxan: CAS Registry Number [143249-88-1]; Drug Data Report 2001, 23, 754-755;
9. Idazoxan: CAS Registry Number [79944-58-4]; Drugs Future 1996, 21, 965-966;
10. b) Fipamezole: CAS Registry Number [150586-58-6]; Drugs Future 2003, 28, 14-17.
11. 2 antagonists: F. J. Oritz-Alonzo, W. H. Herman, B. J. Gertz, V. C. Williams, M. J. Smith, J. B. Halter, Metab. Clin. Exp. 1991, 40, 1160-1167.
12. J. K. Harrison, W. R. Pearson, K. R. Lynch, Trends Pharmacol. Sci. 1991, 12, 62-67.
13. N. L. Schramm, M. P. McDonald, L. E. Limbird, J. Neurosci. 2001, 21, 4875-4882;
14. J. D. Altman, A. U. Trendelenburg, L. MacMillan, D. Bernstein, L. Limbird, K. Starke, B. K. Kobilka, L. Hein, Mol. Pharmacol. 1999, 56, 154-161;
15. E. MacDonald, B. K. Kobilka, M. Scheinin, Trends Pharmacol. Sci. 1997, 18, 211-219;
16. R. E. Link, K. Desai, L. Hein, M. E. Stevens, A. Chruscinski, D. Bernstein, G. S. Barsh, B. K. Kobilka, Science 1996, 273, 803-805;
17. L. B. MacMillan, L. Hein, M. S. Smith, M. T. Piascik, L. E. Limbird, Science 1996, 273, 801-803.
18. Atipamezole is used in animal health care: CAS Registry Number [104054-27-5]; Drugs Future 1996, 21, 534-535.
19. Selected examples of cyclopropanes used as a conformational restriction device: F. Gnad, M. Poleschak, O. Reiser, Tetrahedron Lett. 2004, 45, 4277-4280;
20. A. Reichelt, C. Gaul, R. R. Frey, A. Kennedy, S. F. Martin, J. Org. Chem. 2002, 67, 4062-4075;
21. Z. Szakonyi, F. Fülöp, D. Tourwé, N. De Kimpe, J. Org. Chem. 2002, 67, 2192-2196;
22. Y. Kazuta, A. Matsuda, S. Shuto, J. Org. Chem. 2002, 67, 1669-1677;
23. S. Shuto, K. Yoshii, A. Matsuda, Jpn. J. Pharmacol. 2001, 85, 207-213;
24. A. A. Cordi, I. Berque-Bestel, T. Persigand, J.-M. Lacoste, A. Newman-Tancredi, V. Audinot, M. J. Millan, J. Med. Chem. 2001, 44, 787-805;
25. S. F. Martin, M. P. Dwyer, B. Hartmann, K. S. Knight, J. Org. Chem. 2000, 65, 1305-1318;
26. J. Salaun, Top. Curr. Chem. 2000, 207, 1-67.
27. While this work was in progress, the Orion Corporation published a patent application in which 1a (R = H) is included in the generic structure claimed. In this application, 1a was said to be prepared through a Simmons-Smith's cyclopropanation performed on inden-2-yl-4-(1-protected-imidazole). However, neither an experimental protocol nor characterization data were provided to support structure identification: Orion Corporation, New Polycyclic Indanylimidazoles with Alpha2 Adrenergic Activity, WO 85698, 2001; Chem. Abstr. 2001, 135, 357928.
28. th ed. (Ed.: S. Budavari), Merck Research Laboratories: Whitehouse Station, N.J., 1996, p. 3657 and 6790.
29. R. B. Woodward, R. Hoffmann, Angew. Chem. Int. Ed. Engl. 1969, 8, 781-932.
30. M. P. Doyle, M. A. McKervey, T. Ye, Intermolecular Cyclopropanation and Related Addition Reactions. Modern Catalytic Methods for Organic Synthesis with Diazo Compounds, John Wiley & Sons, New York, 1998, ch. 4.
31. H. Lebel, J.-F. Marcoux, C. Molinaro, A. B. Charette, Chem. Rev. 2003, 103, 977-1050;
32. M. P. Doyle, M. A. McKervey, T. Ye, Intramolecular Cyclopropanation and Related Addition Reactions. Modern Catalytic Methods for Organic Synthesis with Diazo Compounds, John Wiley & Sons, New York, 1998, ch. 5.
33. a) M. Popovici, V. I. M. Elian, C. D. Nenitzescu, Rev. Roum. Chim. 1967, 12, 583-588: (Chemical Equation Presented)
34. b) M. F. Fawzi, C. D. Gutsche, J. Org. Chem. 1966, 31, 1390-1393: (Chemical Equation Presented)
35. c) For an attempted cyclopropanation on diazo alkynyl ketones: P. H. Mueller, J. M. Kassir, M. A. Semones, M. D. Weingarten, A. Padwa, Tetrahedron Lett. 1993, 34, 4285-4288.
36. The acids 5a,f,h were prepared by Wittig olefinations of the sodium salt of benzoic acid- 2-carboxaldehyde (5a,h) and 2-methylketone (5f) with the appropriate phosphonium ylide, according to: R. K. Howe, F. M. Schleppnik, J. Heterocycl. Chem. 1981, 19, 721-725. The Wittig reaction with ethyltriphenylphosphonium bromide provided a mixture of diastereomers 5e/5d (66:34) from which pure 5e could be crystallized. Application of the Wittig route to the preparation of 5c gave an inseparable mixture of diastereomers 5c/5b (58:42).
37. Consequently, 5c was synthesized by Pd-coupling between ethyl 2-iodo-carboxylate and propyne according to: Q. Zhang, C. Shi, H.-R. Zhang, K. K. Wang, J. Org. Chem. 2000, 65, 7977-7983.
38. Partial hydrogenation of the triple bond with a Lindlar catalyst under the conditions of Campos (K. R. Campos, M. Journet, D. Cai, J. J. Kowal, S. Lee, R. D. Larsen, P. J. Reider, J. Org. Chem. 2003, 68, 2338-2342) produced the Z-alkene in 50% yield (over two steps) with high diastereoselectivity (5c/5b = 99:1).
39. 2 furnished compounds E-5 selectively.
40. Compounds 5a, 5f, 5h, (E,Z)-5b-e and (E,Z)-5g were known: R. S. Mali, S. R. Patil, B. K. Kulkarni, S. N. Yeola, Indian J. Chem. Sect. B 1990, 29, 319-321;
41. D. Hellwinkel, G. Aulmich, M. Melan, Chem. Ber. 1981, 114, 86-108;
42. G. Berti, G. Kabas, A. Marsili, Annali di Chimica (Rome) 1959, 49, 1994-2010.
43. D. W. Brooks, L. D.-L. Lu, S. Masamune, Angew. Chem. Int. Ed. Engl. 1979, 18, 72-74.
44. H. M. L. Davies, W. R. Cantrell, K. R. Romines, J. S. Baum, Org. Synth. 1993, 70, 93-100;
45. J. S. Baum, D. A. Shook, H. M. L. Davies, H. D. Smith, Synth. Commun. 1987, 17, 1709-1716.
46. anti (≈ 10 Hz) according to: L. M. Jackman, S. Sternhell, Applications of Nuclear Magnetic Resonance Spectroscopy in Organic Chemistry, 2nd ed., Pergamon Press, Elmsford, N.Y., 1969, ch. 4-2. For compounds 2b-d, 2g, and 7b-e, these are collected in the Supporting Information.
47. D. O. Morgan, W. D. Ollis, S. P. Stanforth, Tetrahedron 2000, 56, 5523-5534;
48. N. C. Yang, L. C. Lin, A. Shani, S. S. Yang, J. Org. Chem. 1969, 34, 1845-1848.
49. M. P. Doyle, Chem. Rev. 1986, 86, 919-939.
50. M. Yan, W.-J. Zhao, D. Huang, S.-J. Ji, Tetrahedron Lett. 2004, 45, 6365-6367;
51. M. P. Doyle, M. A. McKervey, T. Ye, Intermolecular Cyclopropanation and Related Addition Reactions. Modern Catalytic Methods for Organic Synthesis with Diazo Compounds, John Wiley & Sons, New York, 1998;
52. M. E. Alonso, R. Fernandez, Tetrahedron 1989, 45, 3313-3320.
53. G. A. Olah, M. Arvanaghi, L. Ohannesian, Synthesis 1986, 770-772;
54. C. T. West, S. J. Donnelly, D. A. Kooistra, M. P. Doyle, J. Org. Chem. 1973, 38, 2675-2681.
55. Compounds bearing an alkyl substituent at C-1 or C-1a on the cyclopropane did not withstand benzylic reduction. Thus, we observed extensive decomposition of 7c-f under the reaction conditions (TLC analysis). We also tried to reduce 7b under nonprotic acidic conditions following the method of S. Chandrasekhar, Ch. Raji Reddy, B. Nagendra Babu, J. Org. Chem. 2002, 67, 9080-9082. This protocol, however, did not lead to significant improvements.
56. a) Pierre Fabre Médicament Nouveaux Composés Imidazolidiques, Leur Procédé de Préparation et Leur Utilisation à Titre de Médicaments, WO 097611, 2003; Chem. Abstr. 2003, 139, 395933;
57. b) Pierre Fabre Médicament Nouveaux Dérivés de Tricyclo-imidazolines, Leur Procédé de Préparation et Leur Utilisation à Titre de Médicaments, WO 068755, 2003; Chem. Abstr. 2003, 139, 180064.
58. D. F. Taber, R. J. Herr, S. K. Pack, J. M. Geremia, J. Org. Chem. 1996, 61, 2908-2910.
59. a) G. Maas, "Synthetic Applications of 1,3-Dipolar Cycloaddition Chemistry toward Heterocycles and Natural Products" (Eds.: A. Padwa, W. H. Pearson) in The Chemistry of Heterocyclic Compounds 59, John Wiley & Sons, New York, 2002, ch. 8, pp. 592-601 and references cited therein;
60. b) J. Vebrel, E. Cerutti, R. Carrié, C. R. Acad. Sc. Paris 1979, 288, série C, 363-366.
61. 3J = 1.2 Hz, indicative of a dihedral angle of approximately 100°. L. M. Jackman, S. Sternhell, Applications of Nuclear Magnetic Resonance Spectroscopy in Organic Chemistry, 2nd ed., Pergamon Press, Elmsford, N.Y., 1969, ch. 4-2.
62. II carboxylates to form complexes with olefins has been, however, questioned: A. J. Anciaux, A. J. Hubert, A. F. Noels, N. Petiniot, P. Teyssié, J. Org. Chem. 1980, 45, 695-702.
63. A. S. Kende, X.-C. Guo, Tetrahedron Lett. 2001, 42, 1233-1235.
64. a) C. L. Reddy, M. Nagarajan, Tetrahedron Lett. 1988, 29, 4151-4152;
65. 3CN in a quartz reaction vessel.
66. G. Neef, U. Eder, G. Sauer, J. Org. Chem. 1981, 46, 2824-2826.
67. S. Elz, Z. Naturforsch., Teil B 1987, 42, 238-242.
68. Ketones 20 were prepared by adding MeLi to the acids 9 and then brominating 20 to 21 via their silylenol ethers: L. Blanco, P. Amice, J. M. Conia, Synthesis 1976, 194-196.
69. A. M. van Leusen, F. J. Schaart, D. van Leusen, J. Royal Netherlands Chem. Soc. 1979, 98, 258-262.
70. K. Ninomiya, T. Shioiri, S. Yamada, Tetrahedron 1974, 30, 2151-2157.
71. Examples of stable compounds where a basic amino group is attached to cyclopropanes: R. P. Wurz, A. B. Charette, J. Org. Chem. 2004, 69, 1262-1269;
72. A. Armstrong, J. N. Scutt, Org. Lett. 2003, 5, 2331-2334.
73. M. Z. Gao, D. Kong, A. Clearfield, R. A. Zingaro, Tetrahedron Lett. 2004, 45, 5649-5652;
74. H. L. M. Davies, G. H. Lee, Org. Lett. 2004, 6, 1233-1236;
75. H. Lebel, J.-F. Marcoux, C. Molinaro, A. B. Charette, Chem. Rev. 2003, 103, 977-1050;
76. H. M. L. Davies, S. A. Panaro, Tetrahedron 2000, 56, 4871-4880;
77. H. M. L. Davies, Aldrichimica Acta 1997, 30, 107-114.
78. 4.
79. In the cyclopropanation of 3a, the enantiomeric excess (ee) was determined on the acid 27; for compound 4b, ee was determined on the ester 2b; both by chiral HPLC (Chiralpack AD, Daicel).
80. a) D. F. Taber, S. A. Saleh, R. W. Korsmeyer, J. Org. Chem. 1980, 45, 4699-4702;
81. b) H. M. L. Davies, Jr., W. R. Cantrell, Tetrahedron Lett. 1991, 32, 6509-6512.
82. Separations of the enantiomers from (±)-1a and (±)-2b were effected by preparative HPLC on chiral stationary phase (Chiralpack AD, Daicel).